Clinical stage biopharmaceutical company: Dare Bioscience (DARE)

Daré Bioscience, Inc. (NASDAQ: DARE) was founded in 2005 and is headquartered in San Diego, California, with 5 full-time employees. It is a clinical stage biopharmaceutical company that focuses on the development and marketing of female reproductive health products in the United States.

Dare Bioscience

Dare Bioscience (DARE):

Daré Bioscience® is a clinical-stage biopharmaceutical company dedicated to promoting the development of innovative products for female reproductive health. The company’s mission is to identify, develop and promote a diverse portfolio of new therapies, expand treatment options, improve outcomes and promote convenience for women. The initial research direction of Daré Bioscience® is the prevention of pregnancy (contraception), sexual and vaginal health, and fertility.

Daré Bioscience® plans to develop treatments in contraception, vaginal health, sexual health and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorders (frigidity).

Daré Bioscience has signed a licensing and cooperation agreement with Strategic Science and Technologies-D, LLC and Strategic Science Technologies, LLC to develop and commercialize products for female indications related to female sexual dysfunction and/or female reproductive health.

Notify of
Inline Feedbacks
View all Intels

China stocks: Fintech solutions provide commodity Titanium Technology Holdings Pintec Technology Holdings Limited (PT)

Clinical stage biopharmaceutical company: Sorrento Medical Sorrento Therapeutics (SRNE)